The price of Firdapse—prescribed to patients with Lambert-Eaton myasthenic syndrome (LEMS) is now $375,000 per year after Catalyst Pharmaceuticals secured exclusive rights to market the medication for the next seven years.
For the past twenty years, patients with the disease have been able to access a version of the drug—known as 3,4-DAP—for free from Jacobus Pharmaceutical through the Food and Drug Administration's (FDA) compassionate use program.
However, due Catalyst's licensing rights, that's no longer possible.
https://www.commondreams.org/news/2019/02/04/drug-treat-rare-disease-used-cost-patients-0-now-its-375000-and-sanders-demanding
For the past twenty years, patients with the disease have been able to access a version of the drug—known as 3,4-DAP—for free from Jacobus Pharmaceutical through the Food and Drug Administration's (FDA) compassionate use program.
However, due Catalyst's licensing rights, that's no longer possible.
https://www.commondreams.org/news/2019/02/04/drug-treat-rare-disease-used-cost-patients-0-now-its-375000-and-sanders-demanding
No comments:
Post a Comment